Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine/prilocaine - Plethora Solutions

Next Previous
X
Search
Drug Profile

Lidocaine/prilocaine - Plethora Solutions

Alternative Names: Fortacin; Prilocaine Lidocaine Plethora; Prilocaine/lidocaine; PSD-502; SENSTEND; Tempe

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plethora Solutions
  • Class Acetanilides; Anilides; Class Ib antiarrhythmics; Erectile dysfunction therapies; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Premature ejaculation
  • Discontinued Pain

Most Recent Events

  • 01 Dec 2021 Plethora Solutions completes a phase II trial for Premature ejaculation in USA (Topical) (NCT03578783)
  • 02 Dec 2020 Wanbang Pharmaceutical receives approval from the National Medical Products Administration (NMPA) to submit the investigational new drug (IND) for Clinical Trial Approval (CTA) for Premature ejaculation in China
  • 17 Nov 2020 Wanbang Pharmaceutical expects to receive investigational new drug (IND) application approval from the National Medical Products Administration (NMPA) for Premature ejaculation by the end of first quarter of 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top